2.54 USD
0 (0%)
2.5484 USD
+0.01 (+0.33%)
Overall BDTX gets a fundamental rating of 4 out of 10. We evaluated BDTX against 529 industry peers in the Biotechnology industry. BDTX has an excellent financial health rating, but there are some minor concerns on its profitability. BDTX has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BDTX was profitable.
In the past year BDTX had a positive cash flow from operations.
In the past 5 years BDTX always reported negative net income.
BDTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BDTX has a better Return On Assets (13.62%) than 94.52% of its industry peers.
Looking at the Return On Equity, with a value of 17.03%, BDTX belongs to the top of the industry, outperforming 94.90% of the companies in the same industry.
With an excellent Return On Invested Capital value of 6.74%, BDTX belongs to the best of the industry, outperforming 93.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| ROIC | 6.74% |
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 30.69%, BDTX belongs to the best of the industry, outperforming 95.84% of the companies in the same industry.
With an excellent Operating Margin value of 17.33%, BDTX belongs to the best of the industry, outperforming 93.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.33% | ||
| PM (TTM) | 30.69% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BDTX has more shares outstanding
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.40, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.40, BDTX is doing good in the industry, outperforming 61.25% of the companies in the same industry.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 0.4 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 8.94 indicates that BDTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.94, BDTX is doing good in the industry, outperforming 78.26% of the companies in the same industry.
A Quick Ratio of 8.94 indicates that BDTX has no problem at all paying its short term obligations.
BDTX's Quick ratio of 8.94 is fine compared to the rest of the industry. BDTX outperforms 78.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 |
3. Growth
3.1 Past
BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 127.07%, which is quite impressive.
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
BDTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y138.15%
EPS Next 2Y20.91%
EPS Next 3Y6.09%
EPS Next 5Y10.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.06, the valuation of BDTX can be described as very cheap.
Based on the Price/Earnings ratio, BDTX is valued cheaper than 98.30% of the companies in the same industry.
BDTX is valuated cheaply when we compare the Price/Earnings ratio to 26.38, which is the current average of the S&P500 Index.
BDTX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.06 | ||
| Fwd PE | N/A |
4.2 Price Multiples
BDTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BDTX is cheaper than 99.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.76 | ||
| EV/EBITDA | -7.65 |
4.3 Compensation for Growth
BDTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y20.91%
EPS Next 3Y6.09%
5. Dividend
5.1 Amount
No dividends for BDTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.54
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.45%
Inst Owner Change-1.13%
Ins Owners0.6%
Ins Owner Change0.22%
Market Cap144.70M
Revenue(TTM)70.00M
Net Income(TTM)21.48M
Analysts86.67
Price Target9.44 (271.65%)
Short Float %10.85%
Short Ratio4.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.9%
Min EPS beat(2)24.48%
Max EPS beat(2)37.31%
EPS beat(4)4
Avg EPS beat(4)1123.98%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)572.61%
EPS beat(12)12
Avg EPS beat(12)384.24%
EPS beat(16)16
Avg EPS beat(16)291.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.78%
PT rev (3m)-5.61%
EPS NQ rev (1m)-6.86%
EPS NQ rev (3m)-2.15%
EPS NY rev (1m)36.69%
EPS NY rev (3m)52.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.06 | ||
| Fwd PE | N/A | ||
| P/S | 2.07 | ||
| P/FCF | 6.76 | ||
| P/OCF | 6.76 | ||
| P/B | 1.15 | ||
| P/tB | 1.15 | ||
| EV/EBITDA | -7.65 |
EPS(TTM)0.36
EY14.17%
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)0.38
FCFY14.79%
OCF(TTM)0.38
OCFY14.79%
SpS1.23
BVpS2.21
TBVpS2.21
PEG (NY)0.05
PEG (5Y)N/A
Graham Number4.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 143.37% | ||
| ROICexgc | 143.37% | ||
| OM | 17.33% | ||
| PM (TTM) | 30.69% | ||
| GM | N/A | ||
| FCFM | 30.57% |
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 171.61% | ||
| Profit Quality | 99.62% | ||
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 | ||
| Altman-Z | 0.4 |
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y138.15%
EPS Next 2Y20.91%
EPS Next 3Y6.09%
EPS Next 5Y10.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y114.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year120.25%
EBIT Next 3Y4.07%
EBIT Next 5Y-1.54%
FCF growth 1Y128.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.65%
OCF growth 3YN/A
OCF growth 5YN/A
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you provide the ChartMill fundamental rating for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a fundamental rating of 4 / 10 to BDTX.
Can you provide the valuation status for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a valuation rating of 5 / 10 to BLACK DIAMOND THERAPEUTICS I (BDTX). This can be considered as Fairly Valued.
Can you provide the profitability details for BLACK DIAMOND THERAPEUTICS I?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for BDTX stock?
The Price/Earnings (PE) ratio for BLACK DIAMOND THERAPEUTICS I (BDTX) is 7.06 and the Price/Book (PB) ratio is 1.15.
Can you provide the financial health for BDTX stock?
The financial health rating of BLACK DIAMOND THERAPEUTICS I (BDTX) is 7 / 10.